

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
2 April 2009 (02.04.2009)

PCT

(10) International Publication Number
WO 2009/042094 A3

(51) International Patent Classification:

C07C 311/18 (2006.01) C07C 311/39 (2006.01)
C07C 311/29 (2006.01) C07C 311/44 (2006.01)(74) Common Representative: MERCK & CO., INC.; 126
East Lincoln Avenue, Rahway, New Jersey 07065-0907
(US).

(21) International Application Number:

PCT/US2008/010972

(22) International Filing Date:

22 September 2008 (22.09.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/995,202 25 September 2007 (25.09.2007) US
61/188,720 12 August 2008 (12.08.2008) US(71) Applicant (for all designated States except US): MERCK
& CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway,
New Jersey 07065-0907 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): COBURN, Craig,
A. [US/US]; 126 East Lincoln Avenue, Rahway, New Jer-
sey 07065-0907 (US). VACCA, Joseph, P. [US/US]; 126
East Lincoln Avenue, Rahway, New Jersey 07065-0907
(US). RAJAPAKSE, Hemaka, A. [LK/US]; 126 East
Lincoln Avenue, Rahway, New Jersey 07065-0907 (US).
JONES, Kristen, L. G. [US/US]; 126 East Lincoln
Avenue, Rahway, New Jersey 07065-0907 (US). NAN-
TERMET, Philippe [US/US]; 126 East Lincoln Avenue,
Rahway, New Jersey 07065-0907 (US). BARROW,
James, C. [US/US]; 126 East Lincoln Avenue, Rah-
way, New Jersey 07065-0907 (US). MOORE, Keith, P.
[US/US]; 126 East Lincoln Avenue, Rahway, New Jersey
07065-0907 (US). THEBERGE, Cory [US/US]; 126 East
Lincoln Avenue, Rahway, New Jersey 07065-0907 (US).
WALJI, Abbas, M. [TZ/US]; 126 East Lincoln Avenue,
Rahway, New Jersey 07065-0907 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK,
LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW,
MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL,
NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG,
CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))


Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

30 July 2009

(54) Title: HIV PROTEASE INHIBITORS



(57) Abstract: Compounds of Formula A are disclosed: (A), wherein X^A , k , R^1 , R^2 , R^3 , R^4 , R^5 , R^{5A} , R^6 and R^7 are defined herein. The compounds encompassed by Formula A include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are

useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2008/010972

A. CLASSIFICATION OF SUBJECT MATTER INV. C07C311/18 C07C311/29 C07C311/39 C07C311/44		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C07C		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BEILSTEIN Data, CHEM ABS Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 2008/077070 A (UNIV MASSACHUSETTS [US]; TIBOTEC PHARM LTD [IE]; SCHIFFER CELIA A [US]) 26 June 2008 (2008-06-26) claim 4	1-4, 10, 11
X	----- NALAM MADHAVI N L ET AL: "Crystal structure of lysine sulfonamide inhibitor reveals the displacement of the conserved flap water molecule in human immunodeficiency virus type 1 protease" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 81, no. 17, 1 September 2007 (2007-09-01), pages 9512-9518, XP002482672 ISSN: 0022-538X Results, figure 4a ----- -/--	1-11
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents :		
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family		
Date of the actual completion of the international search 11 February 2009		Date of mailing of the international search report 23/06/2009
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Pérez Carlón, Raquel

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2008/010972

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	STRANIX B R ET AL: "Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-Acyl aromatic alpha-amino acids" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 16, no. 13, 1 July 2006 (2006-07-01), pages 3459-3462, XP025107392 ISSN: 0960-894X [retrieved on 2006-07-01] table 1; compound 13 -----	1-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2008/010972

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2008077070 A	26-06-2008	NONE	